Abate AS Industries Limited , a company listed on the Bombay Stock Exchange (BSE: 531658), has announced a significant increase in its authorized share capital. The decision, made during a board meeting on October 15, 2025, proposes to raise the company's authorized share capital by 26.6%, from Rs. 158.00 crore to Rs. 200.00 crore.

Key Details of the Capital Increase

The board's decision involves expanding the number of equity shares from 15.80 crore to 20.00 crore, while maintaining the face value of Rs. 10.00 per share. This move is subject to shareholder approval, which will be sought through a postal ballot process.

Approval Process and Corporate Actions

To facilitate the approval process, the company has taken the following steps:

1. Appointed M/s. Lakshmmi Subramanian and Associates as the scrutinizer for the postal ballot.
2. Engaged Central Depository Services (India) Limited as the e-voting facilitator.
3. Set October 17, 2025, as the cut-off date for determining member eligibility for the postal ballot notice.

The increase in authorized share capital, if approved, will require a consequent amendment to the Capital Clause (Clause V) of the company's Memorandum of Association.

Implications and Next Steps

An increase in authorized share capital is often seen as a preparatory step for future fundraising activities or potential stock splits. However, it's important to note that this increase does not immediately impact the company's issued share capital or market capitalization. Shareholders will need to closely monitor future announcements for any plans related to the utilization of this increased capital capacity.

The company will now proceed with the postal ballot process to seek shareholder approval for this significant corporate action. Investors and stakeholders should stay tuned for further updates on the voting results and any subsequent strategic moves by Abate AS Industries Limited.

As per the LODR filing, the board meeting commenced at 4:30 PM and concluded at 4:40 PM on October 15, 2025, indicating a swift decision-making process for this important corporate action.

Abate AS Industries Limited, a leading player in the healthcare and eye care sector, has announced a 1:1 bonus share issue and reported robust financial results for the first quarter.

Bonus Share Issuance

The company's board of directors has approved the issuance of bonus shares in the ratio of 1:1, rewarding shareholders with one new fully paid-up equity share for every existing share held. Key details of the bonus issue include:

• Record Date: July 31, 2025
• Number of Bonus Shares: 7,88,03,228
• Face Value: Rs. 10 per share
• Allotment Date: August 1, 2025

This move is expected to enhance liquidity for shareholders and expand the company's retail investor base. The bonus shares will be credited to eligible shareholders' accounts by August 1, 2025.

Q1 Financial Highlights

Abate AS Industries has reported strong financial performance for the quarter:

The Earnings Per Share (EPS) for the quarter stood at Rs. 0.59.

The company's consolidated financial results demonstrate significant growth compared to the previous year, driven by robust performance across its healthcare and retail segments.

Operational Performance

Abate AS Industries continues to strengthen its position in the eye care market:

• The company operates fully functioning eye hospitals in Perinthalmanna, Calicut, Kannur, and Chennai.
• Plans are underway to expand the hospital network to 44 locations globally.
• The retail division, particularly in Bahrain, has shown strong growth, contributing to both revenue and brand visibility.

Management Commentary

Dr. Adv. A. Samsudeen, Chairman and Non-Executive Director, stated, "Our Q1 results reflect the strength of our diversified business model and the growing demand for quality eye care services. The bonus share issuance underscores our commitment to creating value for our shareholders as we continue to expand our presence both in India and internationally."

Future Outlook

Abate AS Industries is poised for continued growth with several strategic initiatives:

• Expansion of eye hospital network in India and internationally
• Launch of a private university focused on healthcare and innovation
• Continued investment in cutting-edge medical technologies and AI-driven diagnostics

The company's focus on value-based care and ethical practices, combined with its expansion plans, positions it well for sustainable growth in the coming years.

Disclaimer: This article is for informational purposes only and should not be considered as financial advice. Investors are advised to conduct their own research and consult with financial advisors before making investment decisions.